Literature DB >> 32277507

Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period.

M Megna1, G Fabbrocini1, E Camela1, E Cinelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32277507     DOI： 10.1111/jdv.16443

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  2 in total

1.  Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.

Authors:  Thomas Graier; Wolfgang Weger; Paul-Gunther Sator; Wolfgang Salmhofer; Barbara Gruber; Constanze Jonak; Claudia Kölli; Martina Schütz-Bergmayr; Igor Vujic; Gudrun Ratzinger; Nina Häring; Clemens Painsi; Knut Prillinger; Alexander Mlynek; Hans Skvara; Hannes Trattner; Adrian Tanew; Roland Lichem; Christina Ellersdorfer; Franz Legat; Alexandra Gruber-Wackernagel; Angelika Hofer; Erich Schmiedberger; Wolfram Hoetzenecker; Robert Müllegger; Werner Saxinger; Franz Quehenberger; Peter Wolf
Journal:  JAAD Int       Date:  2020-12-26

2.  Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?

Authors:  Matteo Megna; Luca Potestio; Nicola Di Caprio; Andrea Tajani; Gabriella Fabbrocini; Alberto Annunziata
Journal:  Dermatol Ther       Date:  2022-03-14       Impact factor: 3.858
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.